Get started

Healthcare

GE Healthcare Technology | GEHC | Long at $62.25GE Healthcare Technology $NASDAQ:GEHC. An aging and unhealthy population will only create an increased need for healthcare imaging services. Add AI to the diagnostic mix, and imaging will be imperative for routine health maintenance and screening. With a P/E of 15x, debt-to equity of 1x, earnings forecast growth of 8.36% per year, and bullish analyst ratings, this could be a good value play for the patient. Thus, at $62.25, NASDAQ:GEHC is in a personal buy zone. Further drops are possible if trade wars make imaging materials/technology difficult to obtain, but that general statement applies to the whole market at this time... Targets: $70.00 $78.00
NASDAQ:GEHCLong
by WorthlessViews
AGL (Long) - Bucking the overall market trendAs I was scrolling through many many charts, I realized its very difficult these days to find a stock that trades on its own accord, without copying the (very volatile) path of the overall market. But I managed to find one which showed almost no correlation to the recent frenzy - NYSE:AGL Fundamentals The underlying fundamentals of NYSE:AGL are difficul t to say the least, though getting better - hence the recent bump in the share price on the back of a few upgrades from analysts With a P/S of 0.4 we can confidently say the valuation is low, but we can't really blame the investors for taking the share price down - despite an amazing growth rate (from 4.3bn in 2023 to 6bn in 2024), the firm is unable to keep its costs and cash position in check With 6bn in revenue , the firm wasn't able to turn a positive gross profit(!) So, I wouldn't look at it yet as a long-term play, though if the firm can put its finances in order, it could be a large player in the definitely-not-getting-smaller space of senior healthcare But the short-term momentum is intruiging Technicals First thing to note is that fascinating bifurcation from the broader market (see the relative strength indicator on the weekly); NYSE:AGL was nicely treading 6% higher today while AMEX:SPY was bleeding 7% - I appreciate stocks like that during these volatile days Plus,it has momentum - a couple of upgrade sent the stock surging and there is a gap to fill, which I would like to take advantage off Other than that, it doesn't really scream buy, so I am not going to sell it as a high-conviction play (no usual accumulation patterns :/) - I am currently looking at it as a diversification play with a momentum tailwind Trade I bought it on the recent pop higher and plan to hold until it breaks the little bottom it created after it surged (red line) I don't plan to marry the stock for longer, I will give it one chance and if it breaks, then I retreat - potential holding time is about a month , or about 5 U-turns in the US tariff policy The stock can be still entered with the same stop/loss but a slightly worse risk/reward Follow me for more analysis & Feel free to ask any questions you have, I am happy to help If you like my content, Please leave a like, comment or a donation, it motivates me to keep producing ideas, thank you :)
NYSE:AGLLong
by jurajholik
The Collaborative Edge: Pfizer's Innovation Secret? Pfizer's success in the biopharmaceutical industry hinges on its internal capabilities and a strategic embrace of external collaboration. This proactive approach, spanning diverse technological frontiers, fuels innovation across its operations. From partnering with QuantumBasel and D-Wave to optimize production planning using quantum annealing, to collaborating with XtalPi to revolutionize drug discovery through AI-powered crystal structure prediction, Pfizer demonstrates the tangible benefits of cross-industry partnerships. These initiatives showcase a commitment to exploring cutting-edge technologies to enhance efficiency and accelerate the identification of promising drug candidates, ultimately improving patient outcomes and strengthening Pfizer's competitive position. The article highlights specific examples of Pfizer's collaborative endeavors. The Pfizer Healthcare Hub in Freiburg acts as a catalyst, connecting internal needs with external innovation. The successful proof of technology in production planning using quantum annealing resulted in significant time and resource savings. Furthermore, the partnership with XtalPi has dramatically reduced the timeframe for determining the 3-D structure of potential drug molecules, enabling faster and more efficient drug screening. These collaborations exemplify Pfizer's strategic focus on leveraging specialized expertise and advanced technologies from external partners to overcome complex challenges in the pharmaceutical value chain. Beyond these specific projects, Pfizer actively engages with the broader quantum computing landscape, recognizing its transformative potential for drug design, clinical studies, and personalized medicine. Collaborations with technology giants like IBM and fellow pharmaceutical companies underscore the industry-wide interest in harnessing the power of quantum computing. While the technology is still in its early stages, Pfizer's proactive participation in this collaborative ecosystem positions it at the forefront of future healthcare breakthroughs. This commitment to synergy, from basic research to market research, underscores a fundamental belief in the power of working together to drive meaningful advancements in the pharmaceutical industry.
NYSE:PFELong
by UDIS_View
Cracks Appearing in J&J's Armor?Johnson & Johnson, a long-established leader in the global healthcare sector, confronts substantial challenges that raise significant questions about its future trajectory and stock valuation. Foremost among these is the persistent and massive litigation surrounding its talc-based baby powder. With tens of thousands of lawsuits alleging links to cancer, the company's strategy to manage this liability via bankruptcy has been repeatedly struck down by courts, most recently rejecting a $10 billion settlement proposal. This forces J&J to potentially face over 60,000 individual claims in court, introducing immense financial uncertainty and the prospect of staggering legal costs and damages. Compounding these concerns is mounting scrutiny over the company's historical and recent marketing practices. A federal judge recently imposed a $1.64 billion penalty against J&J's pharmaceutical arm for misleading marketing of HIV medications, citing a "deliberate and calculated scheme." This follows earlier multi-million dollar settlements related to alleged improper financial inducements paid to surgeons for orthopaedic implants by its DePuy subsidiary, and tax disputes in India over questionable "professional sponsorship" expenses tied to similar activities. These incidents depict recurring legal and ethical entanglements with significant financial penalties and reputational harm. Taken together, the unresolved talc litigation, substantial financial penalties from marketing violations, and persistent questions regarding ethical conduct create considerable headwinds for Johnson & Johnson. The cumulative impact of ongoing legal battles, potential future liabilities, and damage to its corporate image threatens to drain resources, divert management focus from core operations, and erode investor confidence. These converging factors present tangible risks that could exert significant downward pressure on the company's stock price moving forward.
NYSE:JNJShort
by UDIS_View
Zoetis | ZTS | Long at $156.94Zoetis NYSE:ZTS , the largest global animal health company, generated more than $9 billion in revenue in 2024 and earnings have grown 9.3% per year over the past 5 years. Free cash flow for FY2024 was over $2.2 billion. Dividend consistently raised every year for the past for years (currently 1.28%). The growth of the company isn't expected to slow any time soon, and I believe the animal health care market will grow right alongside the human health care market - if not potentially faster (people love their pets). Thus, at $156.94, NYSE:ZTS is in a personal buy zone. There may be some near-term risk with the potential for a daily price-gap close near $136.00, but I personally view that as an even better buy opportunity (unless fundamentals change). Targets $170.00 $180.00 $200.00
NYSE:ZTSLong
by WorthlessViews
$LLY Long-Term BuyHealthcare could possibly be the next rotation coming out of this tech bull run. Using the Trade Jeanie (Jeanius Screener/Indicator), I was able to see the current technical buy signals happening on NYSE:LLY : Inside a HTF fair value gap (3M timeframe) Took out an untested low (liquidity) The Jeanius Indicator shows green 'Combo' labels every time this same combination of signals happened The Jeanius Screener lets me filter my favorite tickers to see which ones are currently taking out untested lows or liquidity
NYSE:LLYLong
by jeanius_tech
Bausch + Lomb | BLCO | Long at $16.02Bausch + Lomb NYSE:BLCO , a strong name in the eye health world, is trading within my historical simple moving average area and appears to be gaining upward momentum. I usually do not like to enter companies this earlier (more data is always better), but this company has very strong earnings and a solid track record. Earnings are forecasted to grow 57% per year and it's trading at a good value compared to its peers (price-to-book: 0.87x, price-to-sales: 1.17x). Low debt-to-equity (0.74x). Product exposure is across the globe and revenue was $4.8 billion in FY2024. Profitability has fluctuated over the years, and tariffs or other global trade issues are always a concern. Also, it's very early in this stock's history to gauge future performance. I would not exclude a call to the $14.00 area in the near-term, so there absolutely risks with this pick. But, at $16.02, NYSE:BLCO is in a personal buy zone. Targets: $17.50 $20.00
NYSE:BLCOLong
by WorthlessViews
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associated with traditional analgesics. The significance of this development cannot be overstated, as it promises a new era where acute pain can be treated effectively and safely, potentially altering the landscape of medical treatment for millions. Journavx operates by selectively inhibiting NaV1.8, a sodium channel vital for pain signaling, thus preventing pain signals from reaching the brain. This mechanism not only offers relief but does so without the side effects that have long plagued opioid use. The implications for healthcare are profound, offering doctors and patients alike a tool that can redefine how we approach pain management in clinical settings. Vertex's success with Journavx showcases the company's commitment to pioneering treatments that address some of the most pressing needs in modern medicine. Financially, this approval has bolstered Vertex's market position, evidenced by a significant uptick in stock performance following the announcement. With a revenue projection for 2025 set between $11.75 and $12.0 billion, Vertex is not just riding the wave of this single approval but is also expanding its therapeutic horizons. The strategic leadership transitions announced alongside this approval signal a robust plan for future innovation, challenging investors and healthcare professionals to think about the evolving landscape of drug development and patient care.  This moment invites us to ponder the future of pharmaceuticals - one where efficacy does not compromise safety, where innovation in treatment could lead to broader societal benefits by reducing dependency on addictive substances. Vertex's journey with Journavx might just be the beginning of a new chapter in medical science, urging us to envision a world where pain management is humane and humane-centered.
NASDAQ:VRTXLong
by UDIS_View
Figs Inc | FIGS | Long at $5.24Figs Inc $NYSE:FIGS. Technical analysis play first, fundamentals second. My selected historical simple moving average lines have converged with the stock price, which often leads to sideways trading and a reversal in the downward trend (i.e. future price increase). The downward trend is flattening, but that doesn't mean post-earnings drop to $1.50-$2.00 isn't out of the question... The FIGS brand is growing within the healthcare world with significant opportunities overseas. While economic headwinds may impede near/medium-term growth, revenue is anticipated to grow into 2027. EPS is expected to rise from 0.01 in 2024 to 0.20 by 2027. While this is not a "value" play and there is high risk for rug pulls, something may be brewing within the chart for a move up. Tread lightly, however... Targets $6.00 $6.40 $7.00 $8.00
NYSE:FIGSLong
by WorthlessViews
Teladoc Health | TDOC | Long at $9.91Teladoc Health NYSE:TDOC - Initial position started at $9.91 with the potential for the price gap in the $7's to be closed in the near future (likely another entry there unless fundamentals change) Pros: User base of over 90 million and growing Revenue grew from $555 million in 2019 to $2.6 billion through Q3 of 2024 Positive free cash flow since 2021 Low debt (debt to equity ratio around 1x) AI integration and partnership with Amazon and Brightline Historical simply moving average is approaching price, which often leads to a jump or change in downward momentum in the longer-term Cons: Currently unprofitable and not forecast to become profitable over the next 3 years Lots of insider selling and exercising of options No dividend Daily price gap in the $7 dollar range which may close prior to move up Targets through 2027 : $14.20 $20.00 $27.00 $35.00 $55.00 (long-term, positive outlook)
NYSE:TDOCLong
by WorthlessViews
1
Aspen showing upside to R204 despite Trump pulling funds from SAOk this isn't the best formation. We have the price above 20MA but still below 200MA. On the other hand, we have a solid bottom formed and a W Formation along with a Box Formation with it. So with the pull back and the retest, we could get a bounce up which will send the price to potentially R204.60 Even though Trump has pulled funding from South AFrica due to the Expropriation Bill being announced, this will pull funds from Healthcare, to developments and more... But it seems like the Fair value of Aspen is underpriced and the market is likely to turn up from here. SO I am bullish for now.
JSE:APNLong
by Timonrosso
Agilon Health | AGL | Long at $2.24Agilon Health NYSE:AGL Pros: Revenue consistently grew from 2019 ($794 million) to 2023 ($4.3 billion) and through three quarters of 2024 ($5.6 billion). Expected to reach $8.7 billion by 2027. Current debt-to-equity ratio 0.06 (very low) Sufficient cash reserves to fund operations and strategic initiatives Strong membership growth (525,000 as of Q3 2024, a 37% year-over-year increase) Recent insider buying ($2 - $3) and awarding of options Cons: Rising medical costs - currently unprofitable and not forecast to become profitable over the next 3 years No dividend Targets (into 2027): $2.72 $4.00 $5.00 $7.00 $11.50 $16.00
NYSE:AGLLong
by WorthlessViews
BUY Rating: SBC Medical Group – A Compelling Growth StorySBC Medical Group Holdings (NASDAQ: SBC), a leader in end-to-end solutions for aesthetic clinics, has earned a "BUY" rating, reflecting its robust growth trajectory and strategic expansion initiatives. The company’s recent performance and forward-looking plans justify its valuation, presenting an attractive opportunity for investors. Valuation and Market Position Compared with SBC’s current price with a valuation target of $11, underscores its growth potential. Despite facing challenges like fluctuating exchange rates and integration costs from recent acquisitions, the company’s fundamentals remain strong. SBC’s market capitalisation stands at $697 million, supported by an annual revenue estimate of $217 million for 2024, reflecting a year-over-year growth of 12%. While SBC operates in the competitive medical aesthetics space, its comprehensive suite of consulting, marketing, and equipment leasing services distinguishes it from peers. The company’s ability to generate steady revenue and expand profit margins highlights its efficiency in leveraging its unique business model. International Expansion Driving Growth A pivotal driver of SBC's growth is its strategic acquisition of Aesthetic Healthcare Holdings (AHH) in Singapore. AHH operates 21 outlets under established brands like SkinGo! and The Chelsea Clinics. Singapore's business-friendly regulatory environment, strong economic growth, and status as a regional hub make it an ideal base for SBC’s expansion into Southeast Asia. Singapore’s GDP growth and high levels of U.S. foreign direct investment further validate SBC’s choice to focus on the region. This acquisition not only accelerates SBC's regional footprint but also positions the company to capitalise on the growing demand for aesthetic services across Asia. Financial Highlights SBC’s Q3 2024 revenue reached $53.1 million, a 12.3% year-over-year increase, with gross profit rising to $43.2 million and margins improving to 81.5% from 70.9% in the prior year. This growth was driven by a shift toward higher-margin revenue streams, including royalty income (29.6% of revenue) and procurement services (33.1%). The company’s decision to discontinue its lower-margin management services business has further enhanced its profitability. Net income for the quarter was $2.8 million, or $0.03 per share, with strong contributions from franchisee expansion and increased demand for aesthetic treatments. Financial Flexibility SBC's financial position is robust, with $137.4 million in cash and equivalents and less than $15 million in long-term debt as of Q3 2024. This financial flexibility enables the company to fund its growth strategies, including further acquisitions and geographic expansion. Strategic Initiatives Beyond its international expansion, SBC has entered partnerships to enhance customer loyalty and corporate wellness offerings. Its alliance with MEDIROM Healthcare in Japan integrates the loyalty programs of both companies, providing access to over 4 million members. SBC also launched SBC Wellness to offer corporate clients improved employee benefits, tapping into the growing demand for wellness services. Growth Catalysts The rising global acceptance of aesthetic medicine, coupled with SBC’s established expertise in high-demand procedures such as liposuction, breast augmentation, and eyelid surgery, positions the company for continued growth. With low market penetration for these services in Japan (estimated at 10%), there is significant upside as demand grows among younger and middle-aged demographics. Risks and Outlook While SBC faces risks such as foreign exchange fluctuations and potential challenges in integrating new acquisitions, its strong balance sheet and strategic focus mitigate these concerns. As the company continues to execute its growth initiatives, share price appreciation and valuation multiple expansion are likely. Conclusion SBC Medical Group Holdings presents a compelling investment opportunity, with a clear path to growth through strategic international expansion, enhanced profitability, and innovative partnerships. Its current valuation offers an attractive entry point for investors seeking exposure to the growing medical aesthetics sector. With strong financials and a proven business model, SBC is well-positioned to deliver long-term shareholder value.
NASDAQ:SBCLong
by HASHInvests200
The Rapid Growing Malaysia Health Care SectorMalaysia’s healthcare landscape is entering a transformative phase, underpinned by a robust allocation of RM45.3 billion in the 2025 national budget—a 10% increase compared to 2024. This commitment, the second-largest budget allocation after education, underscores the government’s focus on addressing rising healthcare demands, including an ageing population, chronic diseases, and urban-rural healthcare gaps. The government’s strategic initiatives, including RM1.3 billion for hospital upgrades and RM300 million for dilapidated clinics in rural areas, highlight a push towards more efficient healthcare delivery. Fitch Solutions’ BMI predicts that Malaysia's healthcare expenditure will grow at an impressive compound annual growth rate (CAGR) of 8.7% from 2023 to 2028, outpacing previous estimates. This growth will be fuelled by increased demand for both public and private healthcare services, bolstered by initiatives such as outsourcing public patient care to 91 private hospitals and the gradual rollback of subsidies for higher-income individuals. The shift in subsidies is expected to drive affluent patients towards private healthcare, expanding opportunities for private healthcare providers. Private healthcare companies, especially those involved in preventive care and supplements, stand to benefit significantly from these trends. One notable player is Nasdaq-listed Agape ATP Corporation (ATPC), a leading healthcare supplement company in Malaysia. With Malaysia’s emphasis on chronic disease prevention and healthier lifestyles, Agape ATP is well-positioned to meet the rising demand for wellness products. The company’s established reputation and product range make it an attractive choice as the nation prioritises self-sufficiency in medical products and preventive healthcare. Moreover, the government’s New Industrial Master Plan 2030, aimed at strengthening domestic production of medical products, offers additional prospects for growth. By focusing on advanced diagnostic tools and in-vitro diagnostics, Malaysia is setting the stage for a more globally competitive healthcare ecosystem. As healthcare spending increases and demand for quality services rises, companies like Agape ATP are likely to see enhanced opportunities to expand and thrive. For investors, Malaysia’s growing healthcare sector and its well-aligned private players present a compelling case for long-term value.
NASDAQ:ATPCLong
by HASHInvests200
TG Therapeutics forming 3rd baseIs a company that develops and commercializes novel treatments for B-cell diseases The stock initiated a bull trend at the end of 2023 after a breakaway gap and has gained +90% during 2024 and gave 2 opportunities to buy on breakouts Now is forming a 3rd base and may give another opportunity to enter, all this while relative to its sector AMEX:XLV is making new highs According to IBD is not among the industry leaders, but it has a 96 Relative Strength Rating against the SP:SPX
NASDAQ:TGTXLong
by dpuleo19
Can Market Turbulence Create Future Innovation?In a dramatic turn of events that sent shockwaves through the pharmaceutical industry, Novo Nordisk's recent setback with its experimental obesity drug CagriSema presents a fascinating case study in market resilience and scientific progress. The company's stock plummeted 24% after trial results showed a 22.7% weight reduction efficacy, falling short of the anticipated 25% target. Yet, beneath this apparent disappointment lies a deeper story of pharmaceutical innovation and market adaptation. The obesity treatment landscape stands at a pivotal crossroads, with the market experiencing exponential growth from its modest beginnings to a staggering $24 billion industry in 2023. Novo Nordisk's journey, alongside competitor Eli Lilly, exemplifies how setbacks often catalyze breakthrough innovations. The CagriSema trial, involving 3,400 participants, represents a clinical study and a testament to the industry's commitment to addressing global health challenges. Looking ahead, this moment of market recalibration might well be remembered as a turning point in the evolution of obesity treatment. With projections suggesting a potential $200 billion market by the early 2030s, the current turbulence could drive even greater innovation and competition. The fact that only 57% of trial participants reached the highest CagriSema dose points to untapped potential and future opportunities for optimization, suggesting that today's apparent setback might pave the way for tomorrow's breakthroughs.
NYSE:NVOShort
by UDIS_View
Can a Pharmaceutical Giant Rewrite Its Own Destiny?In the complex world of global pharmaceuticals, Teva Pharmaceutical Industries Ltd. emerges as a compelling narrative of strategic reinvention. Under the leadership of CEO Richard Francis, the company has transformed from a struggling enterprise to a potential market leader, executing a bold "Pivot to Growth" strategy that has captured the attention of investors and industry experts alike. The company's remarkable journey reflects corporate resilience and a profound understanding of how strategic focus and innovative thinking can resurrect a seemingly faltering business. Teva's renaissance is characterized by calculated moves that challenge traditional pharmaceutical business models. By strategically divesting its Japanese joint venture, selectively targeting high-potential generic markets, and developing promising drug candidates like Anti-TL1A, the company has demonstrated an extraordinary ability to reimagine its core strengths. The financial metrics tell a compelling story: a 66% market capitalization increase, double-digit revenue growth, and a strategic pipeline that promises future innovation in critical therapeutic areas such as neurology and digestive system treatments. Beyond financial metrics, Teva represents a broader narrative of corporate transformation that extends beyond balance sheets. Its commitment to patient access programs, such as the recent inhaler donation initiative with Direct Relief, reveals a deeper organizational philosophy that intertwines strategic growth with social responsibility. This approach challenges the traditional perception of pharmaceutical companies as purely profit-driven entities, positioning Teva as a forward-thinking organization that understands its broader role in global healthcare ecosystems. The company's journey poses a provocative question to business leaders and investors: Can strategic vision, relentless innovation, and a commitment to patient care truly redefine a corporation's trajectory? Teva's emerging story suggests that the answer is a resounding yes—a testament to the power of adaptive strategy, visionary leadership, and an unwavering commitment to pushing the boundaries of what's possible in the pharmaceutical landscape.
NYSE:TEVALong
by signalmastermind
Can Pharma Innovation Rewrite Healthcare's Future?In the rapidly evolving landscape of medical technology, Eli Lilly emerges as a beacon of transformative potential, challenging conventional boundaries of pharmaceutical innovation. With a strategic masterstroke, the company has positioned itself at the forefront of medical breakthroughs, particularly in the revolutionary realm of weight loss and diabetes treatments. The remarkable Zepbound medication stands as a testament to this vision, demonstrating unprecedented efficacy by enabling patients to lose an average of 20.2% body weight - a figure that not only surpasses competitors but also represents a paradigm shift in medical intervention. The company's financial architecture is equally compelling, reflecting a meticulously crafted approach to growth and shareholder value. With a staggering market capitalization of $722 billion, a 27.4% revenue growth, and an impressive 80.9% gross profit margin, Eli Lilly transcends the traditional pharmaceutical business model. Its recent $15 billion share buyback program and consistent 54-year dividend payment history underscore a strategic philosophy that balances aggressive innovation with prudent financial management, creating a blueprint for sustainable corporate success. Beyond financial metrics and breakthrough medications, Eli Lilly represents something more profound: a vision of healthcare's future where technology, research, and human potential converge. The company's $3 billion manufacturing expansion, commitment to oncology research with drugs like Jaypirca, and continuous investment in cutting-edge medical solutions paint a picture of an organization that sees beyond immediate profit - an entity committed to reshaping human health through relentless innovation and scientific excellence. In an era of unprecedented medical challenges, Eli Lilly stands not just as a pharmaceutical company, but as a harbinger of hope, demonstrating how visionary thinking can transform global health landscapes.
NYSE:LLYLong
by signalmastermind
UNH Bounce - Don't Miss Out On This 15% OpportunityNYSE:UNH dropped after the tragic death of UnitedHealthcare CEO (not UNH Group CEO) as well as public backlash. Nevertheless, as always in such situation, this has nothing to do with the stock itself. As price action traders we do not trade political or news events since those drops have an unimportant impact mid- to long-term. UNH now sits on the support zone at around $550 which was previous resistance. We also filled the daily gap at around $568 completely. We touched the 0.236 Fib from the $273 bottom (from 2020) and the RSI is nearly oversold on the daily. This gives us a got chance for a bounce from this zone up to $600 - $620. Support Levels: $550 $528 Target/Resistance Levels: $600 $622-628
NYSE:UNHLong
by LGNDRY-Capital
1